Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase

Neuropharmacology

Volumn 47, Issue 4, 2004, Pages 558-571

  Svedberg, Marie M ^a   Bednar, Ivan ^a   Nordberg, Agneta ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

4 Nicotinic receptor; 7 Nicotinic receptor; Acetylcholinesterase inhibitor, AChEI; Acetylcholinesterase overexpressing mice; Acetylcholinesterase, AChE; Galantamine; M1 muscarinic receptor; M2 muscarinic receptor

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA BUNGAROTOXIN; CHOLINESTERASE INHIBITOR; GALANTAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; NICOTINIC RECEPTOR; PIRENZEPINE; RECEPTOR SUBTYPE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN CORTEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; FRONTAL CORTEX; GENE OVEREXPRESSION; HIPPOCAMPUS; HUMAN; MOTOR CORTEX; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURONS; PROTEIN BINDING; PROTEIN SUBUNITS; RECEPTORS, MUSCARINIC; RECEPTORS, NICOTINIC;

EID: 4544263877     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.06.009     Document Type: Article

References (32)

1. Alkondon M., Reinhardt S., Lobron C., Hermsen B., Maelicke A., Albuquerque E.X. Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons. II. The rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptor subunits by in situ hybridization. Journal of Pharmacology and Experimental Therapeutics. 271:1994;494-506
2. Andres C., Beeri R., Friedman A., Lev-Lehman E., Henis S., Timberg R., Shani M., Soreq H. Acetylcholinesterase-transgenic mice display embryonic modulations in spinal cord choline acetyltransferase and neurexin I beta gene expression followed by late-onset neuromotor deterioration. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;8173-8178
3. Barnes C.A., Meltzer J., Houston F., Orr G., McGann K., Wenk G.L. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience. 99:2000;17-23
4. Beeri R., Andres C., Lev-Lehman E., Timberg R., Huberman T., Shani M., Soreq H. Transgenic expression of human acetylcholinesterase induces progressive cognitive deterioration in mice. Curret Biology. 5:1995;1063-1071
5. Beeri R., Le Novere N., Mervis R., Huberman T., Grauer E., Changeux J.P., Soreq H. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterase-transgenic mice. Journal of Neurochemistry. 69:1997;2441-2451
6. 3H]nicotine binding sites in human brain. Journal of Neurochemistry. 50:1988;1243-1247
7. 125I]-alpha-bungarotoxin binding in human postmortem brain. Journal of Comparative Neurology. 387:1997;385-398
8. Court J., Martin-Ruiz C., Piggott M., Spurden D., Griffiths M., Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biological Psychiatry. 49:2001;175-184
9. Coyle J., Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biological Psychiatry. 49:2001;289-299
10. Ellman G.L., Courtney D., Andres V.J., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology. 7:1961;88-95
11. Erb C., Troost J., Kopf S., Schmitt U., Loffelholz K., Soreq H., Klein J. Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase. Journal of Neurochemistry. 77:2001;638-646
12. Flores C.M., Davila-Garcia M.I., Ulrich Y.M., Kellar K.J. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. Journal of Neurochemistry. 69:1997;2216-2219
13. Giacobini E. Cholinergic foundations of Alzheimer's disease therapy. Journal of Physiology, Paris. 92:1998;283-287
14. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. Journal of Neurochemistry. 74:2000;237-243
15. Hellström-Lindahl E., Mousavi M., Zhang X., Ravid R., Nordberg A. Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. Brain Research, Molecular Brain Research. 66:1999;94-103
16. Hellström-Lindahl E., Court J., Keverne J., Svedberg M., Lee M., Marutle A., Thomas A., Perry E., Bednar I., Nordberg A. Nicotine reduces Aβ in the brain and cerebral vessels of APPsw mice. European Journal of Neuroscience. 10:2004;2703-2710
17. Nguyen H.N., Rasmussen B.A., Perry D.C. Subtype-selective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. Journal of Pharmacology and Experimental Therapeutics. 307:2003;1090-1097
18. Nilsson-Håkansson L., Lai Z., Nordberg A. Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. European Journal of Pharmacology. 186:1990;301-305
19. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety. 19:1998;465-480
20. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Disease and Associated Disorders. 9:1995;21-27
21. Nordberg A., Hellström-Lindahl E., Lee M., Johnson M., Mousavi M., Hall R., Perry E., Bednar I., Court J. Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). Journal of Neurochemistry. 81:2002;655-658
22. Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. Journal of Neurobiology. 53:2002;479-500
23. Raskind M.A., Peskind E.R., Wessel T., Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology. 54:2000;2261-2268
24. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., Albuquerque E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Molecular Pharmacology. 61:2002;1222-1234
25. Schrattenholz A., Pereira E.F., Roth U., Weber K.H., Albuquerque E.X., Maelicke A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Molecular Pharmacology. 49:1996;1-6
26. Scott L.J., Goa K.L. Galantamine: a review of its use in Alzheimer's disease. Drugs. 60:2000;1095-1122
27. Sherman K.A. Pharmacodynamics of oral E2020 and Tacrine in humans: novel approaches. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;321-328 Birkhauser, Boston, Cambridge
28. Svedberg M.M., Svensson A.L., Johnson M., Lee M., Cohen O., Court J., Soreq H., Perry E., Nordberg A. Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. Journal of Molecular Neuroscience. 18:2002;211-222
29. Svedberg M.M., Svensson A.L., Bednar I., Nordberg A. Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. Neuroscience Letters. 340:2003;148-152
30. Wilcock G.K., Lilienfeld S., Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br. Med. J. 321:2000;1445-1449
31. Woodruff-Pak D.S., Vogel R.W. III, Wenk G.L. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proceedings of the National Academy of Sciences of the United States of America. 98:2001;2089-2094
32. Zhang X., Tian J.Y., Svensson A.L., Gong Z.H., Meyerson B., Nordberg A. Chronic treatments with tacrine and (-)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat. Journal of Neural Transmission. 109:2002;377-392